The company also announced a gross profit of $1.53 billion in Q1, up from $1.47 billion in first quarter of 2013.
Its neurotechnology and spine business saw net sales of $420 million, up from $397 million in the same period last year. Net sales growth was attributed to increased unit volume and changes in product mix as well as an acquisitions.
“Our continued investments in internal innovation, coupled with our recent acquisitions, position us well to meet our customers’ evolving needs,” said Kevin A. Lobo, president and CEO.
More Articles on Devices:
Mazor Robotics 2013 Net Loss Shoots to $20M
Advancement in Lateral Spine Technology: Q&A with Vertebral Technologies, Inc. CEO Dr. Jeffrey Felt
EDGE Orthopaedics Receives FDA 510(k) Clearance for BITE Compression Screws
